DE69531387D1 - Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie - Google Patents

Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie

Info

Publication number
DE69531387D1
DE69531387D1 DE69531387T DE69531387T DE69531387D1 DE 69531387 D1 DE69531387 D1 DE 69531387D1 DE 69531387 T DE69531387 T DE 69531387T DE 69531387 T DE69531387 T DE 69531387T DE 69531387 D1 DE69531387 D1 DE 69531387D1
Authority
DE
Germany
Prior art keywords
vectors
adenovirus
gene therapy
methods
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531387T
Other languages
English (en)
Other versions
DE69531387T2 (de
Inventor
Abraham Bout
Bekkum Dirk Willem Van
Domenico Valerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of DE69531387D1 publication Critical patent/DE69531387D1/de
Application granted granted Critical
Publication of DE69531387T2 publication Critical patent/DE69531387T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69531387T 1994-08-16 1995-08-15 Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie Expired - Lifetime DE69531387T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202322 1994-08-16
EP94202322 1994-08-16

Publications (2)

Publication Number Publication Date
DE69531387D1 true DE69531387D1 (de) 2003-09-04
DE69531387T2 DE69531387T2 (de) 2004-04-22

Family

ID=8217101

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531387T Expired - Lifetime DE69531387T2 (de) 1994-08-16 1995-08-15 Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie

Country Status (8)

Country Link
US (1) US6204052B1 (de)
EP (2) EP0707071B1 (de)
JP (1) JPH08238092A (de)
AT (1) ATE246252T1 (de)
AU (1) AU711269B2 (de)
CA (1) CA2156132A1 (de)
DE (1) DE69531387T2 (de)
DK (1) DK0707071T3 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224113T5 (es) * 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
EP0784690B1 (de) * 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
ES2333425T5 (es) * 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
EP0834323A1 (de) * 1996-09-30 1998-04-08 Introgene B.V. Cytokin-Gentherapie für die Behandlung von malignen Tumoren
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
NZ500657A (en) * 1997-07-11 2002-11-26 Introgene B Interleukin-3 gene therapy for cancer
CN100352511C (zh) * 1997-08-13 2007-12-05 Uab研究基金会 局部应用基因载体的疫苗接种
SI1007717T1 (sl) * 1997-08-29 2006-10-31 Biogen Idec Inc Metode in sestavki za terapije raka z uporabo genov, ki kodirajo interferon-beta
DK1007717T3 (da) * 1997-08-29 2006-05-29 Biogen Idec Inc Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO1999041398A1 (en) * 1998-02-11 1999-08-19 Genvec, Inc. Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
DE69933856D1 (de) 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
CN1074459C (zh) * 1998-11-25 2001-11-07 马丁 重组腺病毒－胸苷激酶构建体及其获得方法和用途
EP1020520A1 (de) * 1999-01-15 2000-07-19 Introgene B.V. Verhinderung der immunverwandten Entfernung der Zellen aus dem Säugetierkörper, mutante PML Moleküle dafür
EP1200622A4 (de) 1999-07-06 2004-12-22 Merck & Co Inc Hiv impfstoff aus einem das gag-gen tragenden adenovirus
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
EP1230378B1 (de) * 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. Ein oncolytisches adenovirus
US7125549B2 (en) * 2000-05-31 2006-10-24 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP1203819A3 (de) * 2000-10-06 2002-08-07 Transgene S.A. Entzündungshemmende Vektoren
WO2003024384A2 (en) * 2001-09-20 2003-03-27 Magnum Therapeutics Improved methods for treatment with viral vectors
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US20030228276A1 (en) * 2002-04-09 2003-12-11 Pitossi Fernando Juan Neuroprotective and neurogenerative effects of the long-term expression of TNF alpha in the substantia nigra and a new animal model for Parkinson's disease
WO2006020996A2 (en) * 2004-08-11 2006-02-23 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
AU2006299079A1 (en) 2005-09-30 2007-04-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
US8642274B2 (en) 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN111658770A (zh) * 2019-03-05 2020-09-15 周文云 P14.7蛋白质及其作为疫苗佐剂的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
JPH06501161A (ja) * 1990-09-14 1994-02-10 ザ　ジョーンズ　ホプキンス　ユニバーシティー 抗腫瘍免疫性の強化と遺伝子治療のための組成物及び方法
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (de) * 1992-12-03 1995-09-27 Genzyme Corporation GENTHERAPIE DER MYKOVISCIDOSES (kystic fibroses)
AU7019494A (en) * 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ATE304604T1 (de) * 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
ES2310924T3 (es) * 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1995009654A1 (en) 1993-10-01 1995-04-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gene therapy of the nervous system
US6682728B1 (en) 1993-10-13 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Efficient and selective adenoviral-mediated gene transfer into vascular neointima
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0784690B1 (de) * 1994-06-10 2006-08-16 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica

Also Published As

Publication number Publication date
DE69531387T2 (de) 2004-04-22
DK0707071T3 (da) 2003-11-17
AU711269B2 (en) 1999-10-07
EP1369487A3 (de) 2004-04-07
ATE246252T1 (de) 2003-08-15
EP0707071A1 (de) 1996-04-17
US6204052B1 (en) 2001-03-20
EP0707071B1 (de) 2003-07-30
CA2156132A1 (en) 1996-02-17
EP1369487A2 (de) 2003-12-10
JPH08238092A (ja) 1996-09-17
AU2853395A (en) 1996-03-21

Similar Documents

Publication Publication Date Title
DE69531387D1 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
CA2161962A1 (en) Adenovirus vectors for gene therapy
CA2173975A1 (en) Recombinant adenoviral vector and methods of use
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
DE69430071T2 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
HUP0301318A2 (hu) Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel
FI951404A0 (fi) Adenovirusvektoreita vieraiden geenien siirtämiseksi keskushermostojärjestelmän, erityisesti aivojen, soluihin
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
ES2080341T3 (es) Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.
DK2050818T3 (da) Transkriptionsaktivatorer med gradueret transaktiveringspotentiale
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
CA2096222A1 (en) Bifunctional selectable fusion genes
WO2001073060A3 (en) 18221, dual specificity phosphatase and uses thereof
DE69534733D1 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
DK0566554T3 (da) Fremstilling af rekombinante proteiner ved anvendelse af herpesviruspromotorer og VP16-transaktivatorer
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
DE69929530D1 (de) Attenuierte pferdeherpesvirus
DE69940267D1 (de) Wirtszellen, die rekombinantes humanes erythropoietin exprimieren
FI951633A (fi) Erittyvien proteiinien lisääntynyt tuotanto eukaryoottisilla yhdistelmäsoluilla
DE69627109T2 (de) REKOMBINANTES HERPESVIRUS UNTER DER VERWENDUNG DES gB GENPROMOTERS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition